In vitro larvicidal activity of ivermectin and povidone-iodine against Oestrus ovis

PLoS One. 2021 Oct 26;16(10):e0259044. doi: 10.1371/journal.pone.0259044. eCollection 2021.

Abstract

Purpose: To assess the in vitro larvicidal activity of ivermectin and povidone-iodine (PVP-I) against Oestrus ovis, the most frequent cause of external ophthalmomyiasis.

Methods: L1 O. ovis larvae were collected from the nasal boots of sheep slaughtered in local abattoirs and transferred onto Petri dishes containing mucosal tissue (25 larvae/dish). The larvicidal activity of the following formulations was tested: 1% ivermectin suspension in balanced sterile saline solution (BSSS), 1% ivermectin solution in propylene glycol, propylene glycol, 0.6% PVP-I in hyaluronic acid vehicle (IODIM®), and combination of ivermectin 1% solution and 0.6% PVP-I. One mL of each formulation was added to different Petri dishes containing the larvae. The time needed to kill the larvae was recorded.

Results: 893 larvae were tested. The median time needed to kill the larvae was 46, 44, 11, 6, and 10 minutes for Iodim®, ivermectin 1% suspension, propylene glycol, ivermectin 1% solution, and a combination of ivermectin 1% solution with 0.6% PVP-I, respectively. Kaplan-Meyer analysis disclosed that the survival curves were significantly lower in samples treated with ivermectin 1% solution, ivermectin 1% solution + 0.6% PVP-I, and propylene glycol than in samples receiving other treatments or BSSS.

Conclusion: In this in vitro study, ivermectin 1% solution in propylene glycol, ivermectin 1% solution + 0.6% PVP-I, and propylene glycol alone showed a good, relatively rapid larvicidal activity against O. ovis larvae. Further experimental and clinical studies are necessary to establish whether, or not, these formulations may be considered as potential candidates for the topical treatment for external ophthalmomyiasis caused by O. ovis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diptera / drug effects*
  • Insecticides / pharmacology*
  • Ivermectin / pharmacology*
  • Povidone-Iodine / pharmacology*

Substances

  • Insecticides
  • Ivermectin
  • Povidone-Iodine

Grants and funding

Giovanni Garippa has received research grants by University of Sassari, Italy. Fondo di Ateneo per la ricerca, annualità 2020. Rep. 2465/2020, Prot. 0097985 del 01/09/2020. URL of the University of Sassari: https://www.uniss.it The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.